Document is current
Any future updates will be listed below
-
Authors
Tinka, Pavel
Pokorná, Petra
Kýr, Michal
Pavelka, Zdeněk
Vejmělková, Klára
Pálová, Hana
Neradil, Jakub
Ježová, Marta
Slabý, Ondřej
Štěrba, Jaroslav https://orcid.org/0000-0002-8482-8352
-
Funding
Funding for this research was provided by:
European Reference Network on Paediatric Cancer (EU4Health Programme 2021-2027, EU4Health Programme 2021-2027, EU4Health Programme 2021-2027, EU4Health Programme 2021-2027, EU4Health Programme 2021-2027, EU4Health Programme 2021-2027)
Specific University Research provided by MEYS (MUNI/A/1395/2022, MUNI/A/1395/2022, MUNI/A/1395/2022, MUNI/A/1395/2022, MUNI/A/1395/2022, MUNI/A/1395/2022)
CREATIC funded by European Union's Horizon Europe Coordination and Support Action (101059788, 101059788, 101059788, 101059788, 101059788, 101059788, 101059788)
National Institute for Cancer Research - programme EXCELES (LX22NPO5102, LX22NPO5102, LX22NPO5102, LX22NPO5102, LX22NPO5102, LX22NPO5102)
Ministerstvo Zdravotnictví Ceské Republiky (NV19-03-00562, NV19-03-00562, NV19-03-00562)
Masaryk University
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 5 March 2025
First Online: 16 April 2025
Declarations
:
: The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
: Informed consent was obtained from all subjects and/or their legal guardians prior to conducting molecular analyses, clinical data collection, and administering off-label treatment. The subjects and/or their legal guardians provided their written informed consent to presenting this case series before its publishing. The research was carried out in accordance with the Declaration of Helsinki and approved by the Masaryk University Ethical Committee (approval no. 15/2018 and 26/2019) and the Ethics Committee of University Hospital Brno (approval no. 07-00424).
